Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-EN Version v8-FR
Language English French
Date Updated 2020-11-07 2020-11-06
Drug Identification Number 00613215 00613215
Brand name TEVA-SPIRONOLACTONE TEVA-SPIRONOLACTONE
Common or Proper name TEVA-SPIRONOLACTONE 25MG TABLETS TEVA-SPIRONOLACTONE 25MG TABLETS
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients SPIRONOLACTONE SPIRONOLACTONE
Strength(s) 25MG 25MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100,500 100,500
ATC code C03DA C03DA
ATC description POTASSIUM-SPARING AGENTS POTASSIUM-SPARING AGENTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-08-12 2020-08-12
Estimated end date 2020-11-30 2020-11-30
Actual end date 2020-11-06 2020-11-06
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments